GITNUXREPORT 2025

Pulmonary Fibrosis Statistics

Pulmonary fibrosis affects millions, with limited treatment options and poor prognosis.

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Statistic 1

Inspiratory crackles are a common auscultatory finding in pulmonary fibrosis patients, present in over 80% at diagnosis

Statistic 2

Approximately 60-70% of patients with IPF experience exertional dyspnea

Statistic 3

Pulmonary function tests in pulmonary fibrosis typically show a restrictive pattern, with reduced FVC and TLC

Statistic 4

The use of high-resolution computed tomography (HRCT) imaging is critical for diagnosis, revealing usual interstitial pneumonia (UIP) pattern in approximately 75% of IPF cases

Statistic 5

The main histopathological feature of UIP, the pattern seen most in IPF, includes honeycombing, fibroblastic foci, and temporal heterogeneity

Statistic 6

Exercise intolerance is a common feature, with many patients unable to perform moderate physical activity due to dyspnea

Statistic 7

The average delay from symptom onset to diagnosis of pulmonary fibrosis is approximately 1 year, often due to nonspecific symptoms

Statistic 8

The median time from symptom onset to diagnosis has decreased over the past decade due to improved awareness and diagnostic techniques, from approximately 24 months to 12 months

Statistic 9

Patients with pulmonary fibrosis are at increased risk for lung infections, including bacterial pneumonia and fungal infections, complicating disease management

Statistic 10

Efforts to develop blood-based biomarkers for early detection of pulmonary fibrosis are ongoing, with promising candidates such as MMPs and KL-6 under investigation

Statistic 11

Environmental factors such as smoking are associated with a higher risk of developing pulmonary fibrosis

Statistic 12

Exposure to certain occupational dusts, such as silica and asbestos, increases the risk of developing pulmonary fibrosis

Statistic 13

Current research indicates a genetic predisposition involving mutations in genes such as TERT and TERC in familial pulmonary fibrosis cases

Statistic 14

Environmental air pollution, particularly fine particulate matter, has been linked to increased risk of developing pulmonary fibrosis

Statistic 15

The presence of certain genetic markers, such as MUC5B promoter polymorphism, is associated with increased susceptibility to IPF

Statistic 16

Pulmonary fibrosis affects approximately 5 million people worldwide

Statistic 17

The estimated prevalence of idiopathic pulmonary fibrosis (IPF) ranges from 2 to 29 cases per 100,000 population globally

Statistic 18

IPF is more common in men than women, with a male-to-female ratio of approximately 2:1

Statistic 19

Digital clubbing is observed in about 50% of patients with pulmonary fibrosis

Statistic 20

IPF accounts for about 20-30% of all interstitial lung diseases

Statistic 21

The prevalence of pulmonary fibrosis increases with age, primarily affecting those over 60 years old

Statistic 22

Family history plays a role in pulmonary fibrosis, with 5-20% of cases having a familial component

Statistic 23

Common comorbidities in pulmonary fibrosis include hypertension, coronary artery disease, and gastroesophageal reflux disease, affecting 70% of patients in some studies

Statistic 24

The annual incidence of pulmonary fibrosis is estimated at 3 to 9 cases per 100,000 people globally

Statistic 25

The prevalence of pulmonary fibrosis is higher in Europe and North America compared to Asia, possibly due to environmental and genetic factors

Statistic 26

Men are more likely to develop idiopathic pulmonary fibrosis than women, with a ratio of 2:1

Statistic 27

Less than 10% of idiopathic pulmonary fibrosis patients are diagnosed before the age of 50, indicating it predominantly affects older adults

Statistic 28

Pulmonary hypertension develops in approximately 30-50% of patients with advanced pulmonary fibrosis, complicating prognosis

Statistic 29

Gastroesophageal reflux disease (GERD) is present in up to 86% of IPF patients and may contribute to disease progression

Statistic 30

Pulmonary fibrosis patients often experience anxiety and depression, with prevalence rates of approximately 25-50%, impacting disease management

Statistic 31

The median age at diagnosis for IPF is approximately 66 years old, reflecting its prevalence among older adults

Statistic 32

Pulmonary fibrosis is sometimes associated with autoimmune diseases like rheumatoid arthritis and scleroderma, representing about 20% of cases with interstitial lung disease

Statistic 33

IPF is classified as a rare disease, affecting fewer than 200,000 people in the United States, according to the Orphan Drug Act

Statistic 34

Smoking-related interstitial lung disease (SR-ILD) accounts for a subset of pulmonary fibrosis cases, primarily in heavy smokers

Statistic 35

Pulmonary fibrosis can lead to right-sided heart failure due to increased pulmonary artery pressures, known as cor pulmonale, affecting roughly 15-25% of advanced cases

Statistic 36

Pulmonary fibrosis is increasingly recognized as a heterogeneous disease with various phenotypes providing different prognoses and responses to treatment

Statistic 37

The median survival time after diagnosis of IPF is approximately 3 to 5 years

Statistic 38

Lung transplantation offers a potential cure, with about 50% of transplants in IPF patients surviving beyond five years

Statistic 39

The annual mortality rate for pulmonary fibrosis is estimated at 30-40% globally, highlighting its severity and poor prognosis

Statistic 40

The rate of hospitalizations for pulmonary fibrosis-related complications increases significantly with disease progression, often leading to respiratory failure

Statistic 41

Despite specialist management, the prognosis of pulmonary fibrosis remains poor, with a five-year survival rate similar to many cancers, around 20-25%

Statistic 42

Nintedanib and pirfenidone are the two FDA-approved medications for slowing IPF progression, with clinical trials showing a reduction in FVC decline by approximately 50%

Statistic 43

The global economic burden of idiopathic pulmonary fibrosis is significant, with estimated costs exceeding $5 billion annually in the United States alone

Statistic 44

Smoking cessation can slow the progression of pulmonary fibrosis, emphasizing smoking as a modifiable risk factor

Statistic 45

The use of oxygen therapy in pulmonary fibrosis patients improves survival and quality of life, especially in those with resting hypoxemia

Statistic 46

Women with IPF tend to respond better to certain antifibrotic therapies compared to men, based on clinical trial data

Statistic 47

There is currently no cure for pulmonary fibrosis, but emerging therapies and clinical trials show promise for future treatment options

Statistic 48

The disease burden of pulmonary fibrosis has led to increased research funding, with NIH allocating over $50 million annually for related studies

Statistic 49

Pulmonary rehabilitation programs can improve exercise capacity and quality of life in pulmonary fibrosis patients, with about 70% reporting symptom relief

Statistic 50

Recent advances suggest that antifibrotic drugs may be beneficial in some forms of progressive fibrotic interstitial lung diseases beyond IPF

Statistic 51

Recent clinical trials are investigating the role of biologics and novel anti-inflammatory agents in treating fibrotic lung diseases, with some showing promising preliminary results

Statistic 52

Telemedicine and remote monitoring tools are emerging to help manage pulmonary fibrosis patients, especially in underserved areas, improving adherence to therapy

Statistic 53

The global market for pulmonary fibrosis drugs is projected to reach over $3 billion by 2027, driven by growing research and unmet medical needs

Slide 1 of 53

Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

Pulmonary fibrosis affects approximately 5 million people worldwide
The estimated prevalence of idiopathic pulmonary fibrosis (IPF) ranges from 2 to 29 cases per 100,000 population globally
IPF is more common in men than women, with a male-to-female ratio of approximately 2:1
The median survival time after diagnosis of IPF is approximately 3 to 5 years
Digital clubbing is observed in about 50% of patients with pulmonary fibrosis
Inspiratory crackles are a common auscultatory finding in pulmonary fibrosis patients, present in over 80% at diagnosis
Approximately 60-70% of patients with IPF experience exertional dyspnea
IPF accounts for about 20-30% of all interstitial lung diseases
The prevalence of pulmonary fibrosis increases with age, primarily affecting those over 60 years old
Environmental factors such as smoking are associated with a higher risk of developing pulmonary fibrosis
Family history plays a role in pulmonary fibrosis, with 5-20% of cases having a familial component
Pulmonary function tests in pulmonary fibrosis typically show a restrictive pattern, with reduced FVC and TLC
The use of high-resolution computed tomography (HRCT) imaging is critical for diagnosis, revealing usual interstitial pneumonia (UIP) pattern in approximately 75% of IPF cases

Pulmonary fibrosis, a devastating lung disease affecting over 5 million people worldwide, silently progresses with a median survival of just 3 to 5 years post-diagnosis, highlighting the urgent need for better awareness, early detection, and innovative treatments.

Clinical Features and Diagnostics

Inspiratory crackles are a common auscultatory finding in pulmonary fibrosis patients, present in over 80% at diagnosis
Approximately 60-70% of patients with IPF experience exertional dyspnea
Pulmonary function tests in pulmonary fibrosis typically show a restrictive pattern, with reduced FVC and TLC
The use of high-resolution computed tomography (HRCT) imaging is critical for diagnosis, revealing usual interstitial pneumonia (UIP) pattern in approximately 75% of IPF cases
The main histopathological feature of UIP, the pattern seen most in IPF, includes honeycombing, fibroblastic foci, and temporal heterogeneity
Exercise intolerance is a common feature, with many patients unable to perform moderate physical activity due to dyspnea
The average delay from symptom onset to diagnosis of pulmonary fibrosis is approximately 1 year, often due to nonspecific symptoms
The median time from symptom onset to diagnosis has decreased over the past decade due to improved awareness and diagnostic techniques, from approximately 24 months to 12 months
Patients with pulmonary fibrosis are at increased risk for lung infections, including bacterial pneumonia and fungal infections, complicating disease management
Efforts to develop blood-based biomarkers for early detection of pulmonary fibrosis are ongoing, with promising candidates such as MMPs and KL-6 under investigation

Clinical Features and Diagnostics Interpretation

Pulmonary fibrosis, often lurking undiagnosed for a year despite hallmark crackles in over 80% of patients and a characteristic UIP pattern in 75% on HRCT, leaves many breathless—literally and figuratively—while ongoing research strives to detect it earlier through elusive blood biomarkers, highlighting a pressing need for vigilance and innovation in its complex diagnosis and management.

Environmental and Genetic Risk Factors

Environmental factors such as smoking are associated with a higher risk of developing pulmonary fibrosis
Exposure to certain occupational dusts, such as silica and asbestos, increases the risk of developing pulmonary fibrosis
Current research indicates a genetic predisposition involving mutations in genes such as TERT and TERC in familial pulmonary fibrosis cases
Environmental air pollution, particularly fine particulate matter, has been linked to increased risk of developing pulmonary fibrosis
The presence of certain genetic markers, such as MUC5B promoter polymorphism, is associated with increased susceptibility to IPF

Environmental and Genetic Risk Factors Interpretation

Pulmonary fibrosis, a complex interplay of genetic predispositions and environmental exposures—from smoking and dust inhalation to air pollution—reminds us that our lungs pay a high price when our lifestyle and environment go unchecked.

Epidemiology and Prevalence

Pulmonary fibrosis affects approximately 5 million people worldwide
The estimated prevalence of idiopathic pulmonary fibrosis (IPF) ranges from 2 to 29 cases per 100,000 population globally
IPF is more common in men than women, with a male-to-female ratio of approximately 2:1
Digital clubbing is observed in about 50% of patients with pulmonary fibrosis
IPF accounts for about 20-30% of all interstitial lung diseases
The prevalence of pulmonary fibrosis increases with age, primarily affecting those over 60 years old
Family history plays a role in pulmonary fibrosis, with 5-20% of cases having a familial component
Common comorbidities in pulmonary fibrosis include hypertension, coronary artery disease, and gastroesophageal reflux disease, affecting 70% of patients in some studies
The annual incidence of pulmonary fibrosis is estimated at 3 to 9 cases per 100,000 people globally
The prevalence of pulmonary fibrosis is higher in Europe and North America compared to Asia, possibly due to environmental and genetic factors
Men are more likely to develop idiopathic pulmonary fibrosis than women, with a ratio of 2:1
Less than 10% of idiopathic pulmonary fibrosis patients are diagnosed before the age of 50, indicating it predominantly affects older adults
Pulmonary hypertension develops in approximately 30-50% of patients with advanced pulmonary fibrosis, complicating prognosis
Gastroesophageal reflux disease (GERD) is present in up to 86% of IPF patients and may contribute to disease progression
Pulmonary fibrosis patients often experience anxiety and depression, with prevalence rates of approximately 25-50%, impacting disease management
The median age at diagnosis for IPF is approximately 66 years old, reflecting its prevalence among older adults
Pulmonary fibrosis is sometimes associated with autoimmune diseases like rheumatoid arthritis and scleroderma, representing about 20% of cases with interstitial lung disease
IPF is classified as a rare disease, affecting fewer than 200,000 people in the United States, according to the Orphan Drug Act
Smoking-related interstitial lung disease (SR-ILD) accounts for a subset of pulmonary fibrosis cases, primarily in heavy smokers
Pulmonary fibrosis can lead to right-sided heart failure due to increased pulmonary artery pressures, known as cor pulmonale, affecting roughly 15-25% of advanced cases
Pulmonary fibrosis is increasingly recognized as a heterogeneous disease with various phenotypes providing different prognoses and responses to treatment

Epidemiology and Prevalence Interpretation

With over 5 million affected worldwide—predominantly older men with a family twist and often masked by comorbidities like hypertension and reflux—pulmonary fibrosis silently complicates breathing, revealing an intricate web of genetics, environment, and disease heterogeneity that demands serious attention despite its status as a rare disease.

Prognosis and Disease Outcomes

The median survival time after diagnosis of IPF is approximately 3 to 5 years
Lung transplantation offers a potential cure, with about 50% of transplants in IPF patients surviving beyond five years
The annual mortality rate for pulmonary fibrosis is estimated at 30-40% globally, highlighting its severity and poor prognosis
The rate of hospitalizations for pulmonary fibrosis-related complications increases significantly with disease progression, often leading to respiratory failure
Despite specialist management, the prognosis of pulmonary fibrosis remains poor, with a five-year survival rate similar to many cancers, around 20-25%

Prognosis and Disease Outcomes Interpretation

Despite advances like lung transplants, pulmonary fibrosis's grim statistics—median survival of just 3 to 5 years, a global mortality rate hovering at 30-40%, and a five-year survival akin to serious cancers—highlight it as a relentless disease that demands urgent innovation and early intervention.

Treatment and Management Strategies

Nintedanib and pirfenidone are the two FDA-approved medications for slowing IPF progression, with clinical trials showing a reduction in FVC decline by approximately 50%
The global economic burden of idiopathic pulmonary fibrosis is significant, with estimated costs exceeding $5 billion annually in the United States alone
Smoking cessation can slow the progression of pulmonary fibrosis, emphasizing smoking as a modifiable risk factor
The use of oxygen therapy in pulmonary fibrosis patients improves survival and quality of life, especially in those with resting hypoxemia
Women with IPF tend to respond better to certain antifibrotic therapies compared to men, based on clinical trial data
There is currently no cure for pulmonary fibrosis, but emerging therapies and clinical trials show promise for future treatment options
The disease burden of pulmonary fibrosis has led to increased research funding, with NIH allocating over $50 million annually for related studies
Pulmonary rehabilitation programs can improve exercise capacity and quality of life in pulmonary fibrosis patients, with about 70% reporting symptom relief
Recent advances suggest that antifibrotic drugs may be beneficial in some forms of progressive fibrotic interstitial lung diseases beyond IPF
Recent clinical trials are investigating the role of biologics and novel anti-inflammatory agents in treating fibrotic lung diseases, with some showing promising preliminary results
Telemedicine and remote monitoring tools are emerging to help manage pulmonary fibrosis patients, especially in underserved areas, improving adherence to therapy
The global market for pulmonary fibrosis drugs is projected to reach over $3 billion by 2027, driven by growing research and unmet medical needs

Treatment and Management Strategies Interpretation

While FDA-approved antifibrotic medications have halved FVC decline and telemedicine expands care, the staggering $5 billion annual U.S. cost and the absence of a cure underscore that, despite promising advances and targeted therapies, pulmonary fibrosis remains a formidable health challenge demanding continued innovation and proactive intervention.